MONTREAL--()--Sunshine Biopharma, Inc. (OTCBB: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies. Adva-27a is a small molecule that inhibits Topoisomerase II (Topo2), an enzyme found in abundance in Multi-Drug Resistant breast cancer. The clinical trials will subsequently be conducted at the McGill University Healthcare Center located in Montreal, Canada.
“We believe Adva-27a is a much more effective inhibitor of Topo2 without the risks of toxicity or significant adverse side effects. During in-vitro testing, Adva-27a was seen to be three times more effective in treatment than its current market competitor.”
Dr. Steve Slilaty, the Company’s President and CEO, stated, “We believe Adva-27a is a much more effective inhibitor of Topo2 without the risks of toxicity or significant adverse side effects. During in-vitro testing, Adva-27a was seen to be three times more effective in treatment than its current market competitor.” Dr. Slilaty also stated, “We anticipate completion by the first half of 2012 and if things go as we expect, we anticipate Adva-27a to be available for “compassionate-use” by the end of the trial. We are excited by the challenges ahead and the potential to make a difference in the length and quality of many people's lives throughout the world.”
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.